Cargando…

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review

Immune checkpoint inhibitors (ICIs) have made significant breakthroughs in the treatment of a variety of malignancies. As its use increases, the unique immune-mediated toxicity profile of ICls are becoming apparent. We report a case of immune-related endocrine adverse events (irAE) in a patient with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Liman, Wang, Chao, Ding, Haixia, Shi, Xuelian, Shan, Bin, Zhou, Ruoying, Liang, Ping, Hou, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578961/ https://www.ncbi.nlm.nih.gov/pubmed/37849819 http://dx.doi.org/10.3389/fonc.2023.1190491

Ejemplares similares

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Partial response to niraparib in combination with tislelizumab in a patient with metastatic undifferentiated tonsillar carcinoma: a case report and literature review
por: Zhang, Jing, et al.
Publicado: (2023)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
por: Zhu, Zhe, et al.
Publicado: (2023)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Acetylcholine receptor binding antibody–associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review
por: Wang, Shengnan, et al.
Publicado: (2022)

Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review
por: Yang, Hujuan, et al.
Publicado: (2023)

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
por: Deng, Chao, et al.
Publicado: (2021)

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
por: Li, Teng, et al.
Publicado: (2023)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Severe Thyrotoxicosis Caused by Molar Pregnancy: A Case Report and Review of the Literature
por: Frasik, Christina, et al.
Publicado: (2023)

Efficacy and Safety of Low-Dose Nab-Paclitaxel Plus Tislelizumab in Elderly Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
por: Zhu, Wenyu, et al.
Publicado: (2022)

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer
por: Gao, Jiale, et al.
Publicado: (2023)

Resolution of Thyrotoxicosis-Associated Pulmonary Hypertension With Treatment of Thyrotoxicosis: A Case-Based Report and Literature Review
por: Khan, Zahid, et al.
Publicado: (2022)

Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial
por: Zheng, Rong, et al.
Publicado: (2023)

Thyrotoxicosis
por: Short, A. Rendle
Publicado: (1941)

TIDE: adjuvant tislelizumab plus donafenib combined with transarterial chemoembolization for high-risk hepatocellular carcinoma after surgery: protocol for a prospective, single-arm, phase II trial
por: Qi, Weili, et al.
Publicado: (2023)

Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
por: Zhou, Qihao, et al.
Publicado: (2023)

Neoadjuvant tislelizumab and tegafur/gimeracil/octeracil (S-1) plus oxaliplatin in patients with locally advanced gastric or gastroesophageal junction cancer: Early results of a phase 2, single-arm trial
por: Yin, Yuping, et al.
Publicado: (2022)

Severe Thyrotoxicosis Following Topical Iodine Application
por: Coyne, Kasey, et al.
Publicado: (2021)

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
por: Lu, Changchang, et al.
Publicado: (2022)

Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature
por: Long, Xiang-Yu, et al.
Publicado: (2022)

Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study
por: Cheng, Ke, et al.
Publicado: (2022)

Thyrotoxicosis and Pregnancy
por: Perros, Petros
Publicado: (2005)

Sleep in thyrotoxicosis
por: Sridhar, G. R., et al.
Publicado: (2011)

Thyrotoxicosis and pregnancy
por: Gietka-Czernel, Małgorzata
Publicado: (2013)

Thyrotoxicosis of pregnancy()
por: Labadzhyan, Artak, et al.
Publicado: (2014)

The Treatment of Thyrotoxicosis
por: Dunlop, D. M.
Publicado: (1948)

Thiouracil in Thyrotoxicosis
Publicado: (1948)

Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review
por: Zhang, Yuzhu, et al.
Publicado: (2023)

Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
por: Xu, Li, et al.
Publicado: (2021)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Thyrotoxicosis Presenting With Acute Cholecystitis: A Case Report and Literature Review
por: Elhaj, Maab F, et al.
Publicado: (2021)

Myopathic dysphagia caused by thyrotoxicosis: a case report and review of the literature
por: Alwithenani, Raad, et al.
Publicado: (2022)

Cerebral Venous Thrombosis during Thyrotoxicosis: Case Report and Literature Update
por: Raho, Emanuela Maria, et al.
Publicado: (2023)

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature
por: Yin, Xin, et al.
Publicado: (2022)

Severe transient left ventricular dysfunction induced by thyrotoxicosis
por: Bird-Lake, E.
Publicado: (2011)

SUN-578 Severe Hyperbilirubinemia Due to Graves' Thyrotoxicosis
por: Thampi, Rahul, et al.
Publicado: (2019)

ODP515 Severe thyrotoxicosis caused by subacute thyroiditis
por: Guo, Rong R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jqi4p4ktgq327f51ipv5nck8ls